Andrea Idili
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Andrea Idili has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
- Francesco Ricci
Department of Chemical Sciences and Technologies, University of Rome, Tor Vergata, Via della Ricerca Scientifica, Rome 00133, Italy
22 shared publications - Claudio Parolo
ISGlobal
13 shared publications - Kevin William Plaxco
University of California
9 shared publications - Arben Merkoçi
Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and BIST Barcelona Spain
7 shared publications Alessandro Porchetta
Chemistry Department, University of Rome Tor Vergata, Via della Ricerca Scientifica, Rome 00133, Italy.
5 shared publicationsAlexis Vallée-Bélisle
Laboratory of Biosensors and Nanomachines, Département de Chimie, Départment de Biochimie et Médecine Moléculaire, Université de Montréal, Montréal, Quèbec, Canada H3T 1J4
5 shared publications
Latest Publications
- Open Access
- 18 November 2026
- Published by American Chemical Society (ACS) in ACS Sensors
Architecture-Dependent Effects of Terminal Switching of Thiol Anchors and Methylene Blue Reporters in Electrochemical DNA-Based Sensors
The terminal placement of surface anchors and redox reporters is a fundamental but often under-optimized design parameter in electrochemical DNA-based sensors. Most architectures use a 5’ thiol anchor and a 3’ methylene blue reporter by convention, although switching these terminal modifications can alter probe orientation, target accessibility, reporter behavior, and signal transduction. Here, we systematically investigated the effect of switching thiol anchors and methylene blue reporters across three electrochemical DNA-based sensor architectures: an electrochemical DNA sensor for complementary DNA detection, an electrochemical aptamer-based sensor for Plasmodium falciparum lactate dehydrogenase detection, and an E-DNA scaffold sensor for antibody detection. Terminal switching produced architecture-dependent effects. In asymmetric electrochemical DNA sensors, switching increased signal gain and produced a lower apparent dissociation constant under matched-frequency interrogation (24.1 vs 7.8 nM for ORI and SWI, respectively). In the aptamer-based sensor, switching generated a low-frequency signal-ON response and improved signal gain at selected interrogation frequencies. By contrast, in the E-DNA scaffold sensor, the original orientation outperformed the switched architecture, producing a higher signal change, improved signal-to-background ratio, and faster apparent response kinetics. These results demonstrate that terminal modification placement is not a neutral synthetic choice but a determinant of signal transduction and analytical performance. More broadly, this work establishes terminal switching as a simple design variable for tuning electrochemical DNA, aptamer-based, and scaffold-based sensors through deliberate optimization of terminal architecture.
- 18 November 2026
- Published by American Chemical Society (ACS) in ACS Sensors
Open AccessArchitecture-Dependent Effects of Terminal Switching of Thiol Anchors and Methylene Blue Reporters in Electrochemical DNA-Based Sensors
The terminal placement of surface anchors and redox reporters is a fundamental but often under-optimized design parameter in electrochemical DNA-based sensors. Most architectures use a 5’ thiol anchor and a 3’ methylene blue reporter by convention, although switching these terminal modifications can alter probe orientation, target accessibility, reporter behavior, and signal transduction. Here, we systematically investigated the effect of switching thiol anchors and methylene blue reporters across three electrochemical DNA-based sensor architectures: an electrochemical DNA sensor for complementary DNA detection, an electrochemical aptamer-based sensor for Plasmodium falciparum lactate dehydrogenase detection, and an E-DNA scaffold sensor for antibody detection. Terminal switching produced architecture-dependent effects. In asymmetric electrochemical DNA sensors, switching increased signal gain and produced a lower apparent dissociation constant under matched-frequency interrogation (24.1 vs 7.8 nM for ORI and SWI, respectively). In the aptamer-based sensor, switching generated a low-frequency signal-ON response and improved signal gain at selected interrogation frequencies. By contrast, in the E-DNA scaffold sensor, the original orientation outperformed the switched architecture, producing a higher signal change, improved signal-to-background ratio, and faster apparent response kinetics. These results demonstrate that terminal modification placement is not a neutral synthetic choice but a determinant of signal transduction and analytical performance. More broadly, this work establishes terminal switching as a simple design variable for tuning electrochemical DNA, aptamer-based, and scaffold-based sensors through deliberate optimization of terminal architecture.
- Open Access
- 25 July 2026
- Published by Wiley in Small Structures
- Vol. 7 (7) , e70539
Electrochemical DNA‐Based Biosensors for In Vivo Quantification of a Therapeutic Protein
Inter‐subject pharmacokinetic variability limits the clinical effectiveness of many “biologics”, including monoclonal antibody drugs. This issue can be addressed through therapeutic drug monitoring (TDM), in which clinicians tailor dosing to individual patients based on measured plasma drug concentrations. In practice, TDM is inconvenient because current methods for quantifying protein drugs in blood are labor‐intensive and expensive. In response, here we present an electrochemical DNA‐based biosensor that addresses this issue by enabling rapid, reagentless measurement of plasma concentrations of the antibody drug trastuzumab. The approach supports real‐time, in vivo monitoring in living animals (rats). Specifically, we have systematically compared two distinct sensing architectures, a DNA scaffold sensor and an electrochemical aptamer‐based sensor, before developing an optimized sensor in the latter class that, when challenged in undiluted whole blood, can measure over the entire clinical range of the drug. When implanted in animals, the sensor successfully tracks in vivo drug concentrations and clearly visualizes differences in drug exposure between individual rats following intravenous infusion. Given the ability to generalize EAB sensors to almost any target of interest, this work illustrates a powerful new tool to guide real‐time dosing of biologic therapeutics, enabling personalized treatments of this increasingly important class of drugs.
- 25 July 2026
- Published by Wiley in Small Structures
- Vol. 7 (7) , e70539
Open AccessElectrochemical DNA‐Based Biosensors for In Vivo Quantification of a Therapeutic Protein
Inter‐subject pharmacokinetic variability limits the clinical effectiveness of many “biologics”, including monoclonal antibody drugs. This issue can be addressed through therapeutic drug monitoring (TDM), in which clinicians tailor dosing to individual patients based on measured plasma drug concentrations. In practice, TDM is inconvenient because current methods for quantifying protein drugs in blood are labor‐intensive and expensive. In response, here we present an electrochemical DNA‐based biosensor that addresses this issue by enabling rapid, reagentless measurement of plasma concentrations of the antibody drug trastuzumab. The approach supports real‐time, in vivo monitoring in living animals (rats). Specifically, we have systematically compared two distinct sensing architectures, a DNA scaffold sensor and an electrochemical aptamer‐based sensor, before developing an optimized sensor in the latter class that, when challenged in undiluted whole blood, can measure over the entire clinical range of the drug. When implanted in animals, the sensor successfully tracks in vivo drug concentrations and clearly visualizes differences in drug exposure between individual rats following intravenous infusion. Given the ability to generalize EAB sensors to almost any target of interest, this work illustrates a powerful new tool to guide real‐time dosing of biologic therapeutics, enabling personalized treatments of this increasingly important class of drugs.
- Open Access
- 20 July 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Engineering Cooperative Multi-Domain DNA Probes for Programmable Nucleic Acid Detection
Nucleic acids are powerful recognition elements because base pairing enables straightforward probe design, yet selective target recognition under physiological conditions remains challenging when specificity cannot rely on melting-based discrimination. Here we introduce a programmable multi-domain DNA probe that converts target binding into a cooperative self-assembly process. The recognition sequence is split into two short domains carried on separate strands, each coupled to a programmable stem domain through a flexible linker. Target hybridization increases the effective local concentration of the stems and drives their cooperative assembly into a stable three-way junction. This architecture enables independent control over probe performance: stem length tunes thermodynamic stability and apparent affinity, linker length regulates signal transduction without significantly affecting recognition, and cooperative assembly introduces an activation threshold that sharpens discrimination against mismatched and truncated targets. We demonstrate high sequence specificity with model DNA targets, extend the approach to disease-relevant miRNAs, and show that distinct probes operate orthogonally in a multiplexed format. Finally, we translate the same mechanism to a signal-ON electrochemical platform that supports point-of-care formats and operates directly in whole blood. Multi-domain probe design thus provides a modular, amplification-free strategy for programmable, high-specificity nucleic acid detection.
- 20 July 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessEngineering Cooperative Multi-Domain DNA Probes for Programmable Nucleic Acid Detection
Nucleic acids are powerful recognition elements because base pairing enables straightforward probe design, yet selective target recognition under physiological conditions remains challenging when specificity cannot rely on melting-based discrimination. Here we introduce a programmable multi-domain DNA probe that converts target binding into a cooperative self-assembly process. The recognition sequence is split into two short domains carried on separate strands, each coupled to a programmable stem domain through a flexible linker. Target hybridization increases the effective local concentration of the stems and drives their cooperative assembly into a stable three-way junction. This architecture enables independent control over probe performance: stem length tunes thermodynamic stability and apparent affinity, linker length regulates signal transduction without significantly affecting recognition, and cooperative assembly introduces an activation threshold that sharpens discrimination against mismatched and truncated targets. We demonstrate high sequence specificity with model DNA targets, extend the approach to disease-relevant miRNAs, and show that distinct probes operate orthogonally in a multiplexed format. Finally, we translate the same mechanism to a signal-ON electrochemical platform that supports point-of-care formats and operates directly in whole blood. Multi-domain probe design thus provides a modular, amplification-free strategy for programmable, high-specificity nucleic acid detection.
- Open Access
- 16 July 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Engineering Cooperative Multi-Domain DNA Probes for Programmable Nucleic Acid Detection
Nucleic acids are powerful recognition elements because base pairing enables straightforward probe design, yet selective target recognition under physiological conditions remains challenging when specificity cannot rely on melting-based discrimination. Here we introduce a programmable multi-domain DNA probe that converts target binding into a cooperative self-assembly process. The recognition sequence is split into two short domains carried on separate strands, each coupled to a programmable stem domain through a flexible linker. Target hybridization increases the effective local concentration of the stems and drives their cooperative assembly into a stable three-way junction. This architecture enables independent control over probe performance: stem length tunes thermodynamic stability and apparent affinity, linker length regulates signal transduction without significantly affecting recognition, and cooperative assembly introduces an activation threshold that sharpens discrimination against mismatched and truncated targets. We demonstrate high sequence specificity with model DNA targets, extend the approach to disease-relevant miRNAs, and show that distinct probes operate orthogonally in a multiplexed format. Finally, we translate the same mechanism to a signal-ON electrochemical platform that supports point-of-care formats and operates directly in whole blood. Multi-domain probe design thus provides a modular, amplification-free strategy for programmable, high-specificity nucleic acid detection.
- 16 July 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessEngineering Cooperative Multi-Domain DNA Probes for Programmable Nucleic Acid Detection
Nucleic acids are powerful recognition elements because base pairing enables straightforward probe design, yet selective target recognition under physiological conditions remains challenging when specificity cannot rely on melting-based discrimination. Here we introduce a programmable multi-domain DNA probe that converts target binding into a cooperative self-assembly process. The recognition sequence is split into two short domains carried on separate strands, each coupled to a programmable stem domain through a flexible linker. Target hybridization increases the effective local concentration of the stems and drives their cooperative assembly into a stable three-way junction. This architecture enables independent control over probe performance: stem length tunes thermodynamic stability and apparent affinity, linker length regulates signal transduction without significantly affecting recognition, and cooperative assembly introduces an activation threshold that sharpens discrimination against mismatched and truncated targets. We demonstrate high sequence specificity with model DNA targets, extend the approach to disease-relevant miRNAs, and show that distinct probes operate orthogonally in a multiplexed format. Finally, we translate the same mechanism to a signal-ON electrochemical platform that supports point-of-care formats and operates directly in whole blood. Multi-domain probe design thus provides a modular, amplification-free strategy for programmable, high-specificity nucleic acid detection.
- Open Access
- 11 October 2025
- Published by Elsevier in Current Opinion in Electrochemistry
- Vol. 54
Continuous monitoring of biomolecular targets in vivo using DNA-based electrochemical sensors
- 11 October 2025
- Published by Elsevier in Current Opinion in Electrochemistry
- Vol. 54
Open AccessContinuous monitoring of biomolecular targets in vivo using DNA-based electrochemical sensors
- Open Access
- 16 January 2025
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 274, 117152
An aptamer-based electrochemical sensor for the quantification of the malaria biomarker lactate dehydrogenase
- 16 January 2025
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 274, 117152
Open AccessAn aptamer-based electrochemical sensor for the quantification of the malaria biomarker lactate dehydrogenase
- Open Access
- 10 October 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Structure-switching DNA templates for the rational and predictable control of cell-free transcription
We report here a strategy to control cell-free in vitro transcription of RNA by the rational design of synthetic structure-switching DNA templates. These templates are programmed to undergo a conformational change between an open (OFF) and a closed (ON) state. By controlling the switching equilibrium constant (KS) of such structure-switching templates, we can finely program their transcription efficiency. We have derived a simplified kinetic model that describes our experimental data with high accuracy, supporting the predictability of our approach. Similarly, we have also performed different molecular dynamic simulations that provide an atomistic description of our results. Finally, the introduction of such a conformational change mechanism in target-responsive templates allows rational control of their dynamic range (i.e., the range of target concentration to which they respond) and of their input-output behavior. The structure-switching templates demonstrated in this work are particularly easy to design and provide a highly programmable approach to control cell-free transcription, a feature that can be of great utility in fields like sensing and RNA therapeutics.
- 10 October 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessStructure-switching DNA templates for the rational and predictable control of cell-free transcription
We report here a strategy to control cell-free in vitro transcription of RNA by the rational design of synthetic structure-switching DNA templates. These templates are programmed to undergo a conformational change between an open (OFF) and a closed (ON) state. By controlling the switching equilibrium constant (KS) of such structure-switching templates, we can finely program their transcription efficiency. We have derived a simplified kinetic model that describes our experimental data with high accuracy, supporting the predictability of our approach. Similarly, we have also performed different molecular dynamic simulations that provide an atomistic description of our results. Finally, the introduction of such a conformational change mechanism in target-responsive templates allows rational control of their dynamic range (i.e., the range of target concentration to which they respond) and of their input-output behavior. The structure-switching templates demonstrated in this work are particularly easy to design and provide a highly programmable approach to control cell-free transcription, a feature that can be of great utility in fields like sensing and RNA therapeutics.
- Open Access
- 23 April 2024
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 16 (24) , 30636-30647
Harnessing Bioluminescent Bacteria to Develop an Enzymatic-free Enzyme-linked immunosorbent assay for the Detection of Clinically Relevant Biomarkers
Enzyme-linked immunosorbent assay (ELISA) is the gold standard technique for measuring protein biomarkers due to its high sensitivity, specificity, and throughput. Despite its success, continuous advancements in ELISA and immunoassay formats are crucial to meet evolving global challenges and to address new analytical needs in diverse applications. To expand the capabilities and applications of immunoassays, we introduce a novel ELISA-like assay that we call Bioluminescent-bacteria-linked immunosorbent assay (BBLISA). BBLISA is an enzyme-free assay that utilizes the inner filter effect between the bioluminescent bacteriaAllivibrio fischeriand metallic nanoparticles (gold nanoparticles and gold iridium oxide nanoflowers) as molecular absorbers. Functionalizing these nanoparticles with antibodies induces their accumulation in wells upon binding to molecular targets, forming the classical immune-sandwich complex. Thanks to their ability to adsorb the light emitted by the bacteria, the nanoparticles can suppress the bioluminescence signal, allowing the rapid quantification of the target. To demonstrate the bioanalytical properties of the novel immunoassay platform, as a proof of principle, we detected two clinically relevant biomarkers (human immunoglobulin G and SARS-CoV-2 nucleoprotein) in human serum, achieving the same sensitivity and precision as the classic ELISA. We believe that BBLISA can be a promising alternative to the standard ELISA techniques, offering potential advancements in biomarker detection and analysis by combining nanomaterials with a low-cost, portable bioluminescent platform.
- 23 April 2024
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 16 (24) , 30636-30647
Open AccessHarnessing Bioluminescent Bacteria to Develop an Enzymatic-free Enzyme-linked immunosorbent assay for the Detection of Clinically Relevant Biomarkers
Enzyme-linked immunosorbent assay (ELISA) is the gold standard technique for measuring protein biomarkers due to its high sensitivity, specificity, and throughput. Despite its success, continuous advancements in ELISA and immunoassay formats are crucial to meet evolving global challenges and to address new analytical needs in diverse applications. To expand the capabilities and applications of immunoassays, we introduce a novel ELISA-like assay that we call Bioluminescent-bacteria-linked immunosorbent assay (BBLISA). BBLISA is an enzyme-free assay that utilizes the inner filter effect between the bioluminescent bacteriaAllivibrio fischeriand metallic nanoparticles (gold nanoparticles and gold iridium oxide nanoflowers) as molecular absorbers. Functionalizing these nanoparticles with antibodies induces their accumulation in wells upon binding to molecular targets, forming the classical immune-sandwich complex. Thanks to their ability to adsorb the light emitted by the bacteria, the nanoparticles can suppress the bioluminescence signal, allowing the rapid quantification of the target. To demonstrate the bioanalytical properties of the novel immunoassay platform, as a proof of principle, we detected two clinically relevant biomarkers (human immunoglobulin G and SARS-CoV-2 nucleoprotein) in human serum, achieving the same sensitivity and precision as the classic ELISA. We believe that BBLISA can be a promising alternative to the standard ELISA techniques, offering potential advancements in biomarker detection and analysis by combining nanomaterials with a low-cost, portable bioluminescent platform.
- 13 March 2023
- Published by American Chemical Society (ACS) in ACS Applied Nano Materials
- Vol. 6 (6) , 4151-4161
Rational Approach to Tailor Au–IrO2 Nanoflowers as Colorimetric Labels for Lateral Flow Assays
- 13 March 2023
- Published by American Chemical Society (ACS) in ACS Applied Nano Materials
- Vol. 6 (6) , 4151-4161
Rational Approach to Tailor Au–IrO2 Nanoflowers as Colorimetric Labels for Lateral Flow Assays
- Open Access
- 23 January 2023
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 17 (3) , 1998-2006
Thermo-Programmed Synthetic DNA-Based Receptors
Herein, we present a generalizable and versatile strategy to engineer synthetic DNA ligand-binding devices that can be programmed to load and release a specific ligand at a defined temperature. We do so by re-engineering two model DNA-based receptors: a triplex-forming bivalent DNA-based receptor that recognizes a specific DNA sequence and an ATP-binding aptamer. The temperature at which these receptors load/release their ligands can be finely modulated by controlling the entropy associated with the linker connecting the two ligand-binding domains. The availability of a set of receptors with tunable and reversible temperature dependence allows achieving complex load/release behavior such as sustained ligand release over a wide temperature range. Similar programmable thermo-responsive synthetic ligand-binding devices can be of utility in applications such as drug delivery and production of smart materials.
- 23 January 2023
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 17 (3) , 1998-2006
Open AccessThermo-Programmed Synthetic DNA-Based Receptors
Herein, we present a generalizable and versatile strategy to engineer synthetic DNA ligand-binding devices that can be programmed to load and release a specific ligand at a defined temperature. We do so by re-engineering two model DNA-based receptors: a triplex-forming bivalent DNA-based receptor that recognizes a specific DNA sequence and an ATP-binding aptamer. The temperature at which these receptors load/release their ligands can be finely modulated by controlling the entropy associated with the linker connecting the two ligand-binding domains. The availability of a set of receptors with tunable and reversible temperature dependence allows achieving complex load/release behavior such as sustained ligand release over a wide temperature range. Similar programmable thermo-responsive synthetic ligand-binding devices can be of utility in applications such as drug delivery and production of smart materials.